Samyang Biopharm삼양바이오팜

Samyang Biopharm, listed in November 2025, trades at a high valuation against modest profits, with its share price far below its 52-week high.

Samyang Biopharm reported trailing twelve-month revenue of about ₩28.6B and operating income of about ₩2.7B through H1 2026, a 9.4% operating margin. The shares closed at ₩44,250 on 22 October 2026, giving a market value of about ₩329B, a P/E of about 147 and a P/B of about 1.4. The business has most of its sales overseas and works across medical devices, pharmaceuticals and new drug development.

What stands out

• Profitability is thin relative to the share price: ROE is 0.9% and the P/E is about 147, far above the peers listed in the data (roughly 15 to 83).
• The company holds ₩16.7B in cash against ₩14.0B in borrowings, and its liabilities-to-equity ratio is 16.1%.
• Free cash flow over the trailing period was about ₩3.0B, which is positive but small against the market value.
• The shares are about 90% above the 52-week low of ₩23,250 but about 71% below the 52-week high of ₩150,900, and the one-month return was -5.7%.
• Foreign ownership fell from 4.8% to 4.2% over 60 days, while institutional and retail investors were net sellers over the last 20 days and foreign investors were net buyers.

What to watch

• The Q3 2026 quarterly report and any change to the trailing revenue and margin figures, which are currently based on H1 2026.
• The DCF fair value model in the data gives a base of ₩2,931 with a bear case of ₩1,552 and a bull case of ₩5,423, all far below the current price; the data does not explain this gap.
• Any further filings on shareholder holdings or the largest shareholder's stake, which appeared in August 2026. The data contains no news headlines for the company.